Travere Therapeutics (TVTX) to Release Earnings on Monday

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) will be issuing its earnings results after the market closes on Monday, May 6th. Analysts expect the company to announce earnings of ($0.98) per share for the quarter. Individual interested in participating in the company's earnings conference call can do so using this link.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last issued its quarterly earnings data on Thursday, February 15th. The company reported ($1.16) earnings per share for the quarter, beating analysts' consensus estimates of ($1.27) by $0.11. The company had revenue of $45.06 million during the quarter, compared to analysts' expectations of $41.25 million. Travere Therapeutics had a negative return on equity of 177.97% and a negative net margin of 56.02%. On average, analysts expect Travere Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Travere Therapeutics Stock Performance

Shares of Travere Therapeutics stock traded up $0.07 during trading on Tuesday, reaching $5.53. The company's stock had a trading volume of 1,315,865 shares, compared to its average volume of 1,272,650. The firm has a market cap of $420.89 million, a PE ratio of -3.50 and a beta of 0.58. The company has a 50-day moving average price of $7.23 and a two-hundred day moving average price of $7.64. The company has a current ratio of 3.47, a quick ratio of 3.41 and a debt-to-equity ratio of 1.88. Travere Therapeutics has a fifty-two week low of $5.12 and a fifty-two week high of $22.75.

Analyst Ratings Changes

TVTX has been the subject of several recent research reports. Wells Fargo & Company increased their target price on shares of Travere Therapeutics from $8.00 to $9.00 and gave the stock an "equal weight" rating in a research note on Friday, February 16th. Wedbush reissued an "outperform" rating and issued a $13.00 target price on shares of Travere Therapeutics in a report on Wednesday, April 17th. Guggenheim reaffirmed a "neutral" rating on shares of Travere Therapeutics in a report on Wednesday, March 27th. HC Wainwright raised their target price on shares of Travere Therapeutics from $17.00 to $19.00 and gave the stock a "buy" rating in a research note on Wednesday, April 24th. Finally, Piper Sandler boosted their price target on shares of Travere Therapeutics from $10.00 to $11.00 and gave the stock a "neutral" rating in a research note on Thursday, January 18th. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $18.00.

Insider Buying and Selling

In other news, SVP William E. Rote sold 4,764 shares of the company's stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $8.71, for a total transaction of $41,494.44. Following the completion of the transaction, the senior vice president now owns 80,720 shares of the company's stock, valued at approximately $703,071.20. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, SVP William E. Rote sold 4,764 shares of Travere Therapeutics stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $8.71, for a total value of $41,494.44. Following the transaction, the senior vice president now owns 80,720 shares in the company, valued at $703,071.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Eric M. Dube sold 19,122 shares of the firm's stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $8.70, for a total value of $166,361.40. Following the completion of the transaction, the chief executive officer now owns 350,600 shares in the company, valued at $3,050,220. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 34,773 shares of company stock worth $300,625. 4.06% of the stock is owned by company insiders.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.